StreetInsider.com News Articles

Anaptys Announces Participation at the H.C. Wainwright 28th Annual Global Investment Conference

Tue, 01 Sep 2026 16:15:00 -0400

SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today announced that Chris Murphy, chief financial officer, is scheduled to present at the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, Sept. 15, 2026. The presentation is scheduled to begin at 3:30pm ET.

A live webcast of the presentation will be available on the investor section of the Anaptys website at https://ir.anaptysbio.com/presentations-and-events. A replay of the webcast will be available for at least 30

Anaptys Announces Participation at the H.C. Wainwright 28th Annual Global Investment Conference

Tue, 01 Sep 2026 16:15:00 -0400

Wolfe Research Reiterates Outperform Rating on AnaptysBio (ANAB)

Mon, 31 Aug 2026 05:37:37 -0400

Wolfe Research analyst Andy Chen reiterated an Outperform rating and $78.00 price target on AnaptysBio (NASDAQ: ANAB).

The analyst comments "The contractual language of the amendment between Anaptys and Tesaro/GSK is convoluted, with different phrases supporting each side’s interpretation. GSK can point to language broadly exempting GSK and its affiliates from exclusivity, while Anaptys can point to provisions expressly prohibiting Tesaro from transferring or licensing Jemperli to GSK and preserving Tesaro’s CRE obligations. Based on our interpretation, the contractual language on freedom to operate is not the tiebreaker (because it is ambiguous), but evidence around it. More importantly, Anaptys needs only

AnaptysBio (ANAB) PT Lowered to $70 at TD Cowen

Tue, 25 Aug 2026 07:37:29 -0400

TD Cowen analyst Joseph Thome lowered the price target on AnaptysBio (NASDAQ: ANAB) to $70.00 (from $75.00) while maintaining a Buy rating.

The analyst commented: "GSK announced the FDA accepted Jemperli's sBLA for priority review in previously untreated stage II/III dMMR/MSI-H locally advanced rectal cancer, assigning a February 2027 PDUFA. The application is also eligible for CNPV review and Project Orbis, which could support an earlier decision. We model ~$290MM in peak U.S. sales for the indication."

AnaptysBio (ANAB) PT Lowered to $70 at TD Cowen

Tue, 25 Aug 2026 07:37:29 -0400

TD Cowen analyst Joseph Thome lowered the price target on AnaptysBio (NASDAQ: ANAB) to $70.00 (from $75.00) while maintaining a Buy rating.

Form SCHEDULE 13G/A ANAPTYSBIO, INC Filed by: Sirenia Capital Management LP

Fri, 14 Aug 2026 08:31:00 -0400

si-local-file:///var/storage/secattach/20260814/26925175.html

Form SCHEDULE 13G/A ANAPTYSBIO, INC Filed by: Sirenia Capital Management LP

Fri, 14 Aug 2026 08:31:00 -0400

si-local-file:///var/storage/secattach/20260814/26925175.html

Form 8-K ANAPTYSBIO, INC For: Aug 11

Tue, 11 Aug 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260811/26905592.html

Form 8-K ANAPTYSBIO, INC For: Aug 11

Tue, 11 Aug 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260811/26905592.html

Form 4 ANAPTYSBIO, INC For: Mar 12 Filed by: Lizzul Paul F.

Fri, 07 Aug 2026 17:13:00 -0400

si-local-file:///var/storage/secattach/20260807/26892180.html

Form 4 ANAPTYSBIO, INC For: Mar 12 Filed by: Lizzul Paul F.

Fri, 07 Aug 2026 17:13:00 -0400

si-local-file:///var/storage/secattach/20260807/26892180.html

Form 4 ANAPTYSBIO, INC For: Mar 12 Filed by: Faga Daniel

Fri, 07 Aug 2026 17:12:00 -0400

si-local-file:///var/storage/secattach/20260807/26892173.html

Form 4 ANAPTYSBIO, INC For: Mar 12 Filed by: Faga Daniel

Fri, 07 Aug 2026 17:12:00 -0400

si-local-file:///var/storage/secattach/20260807/26892173.html

Form 8-K ANAPTYSBIO, INC For: Jul 28

Thu, 30 Jul 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260730/26843511.html

Form 8-K ANAPTYSBIO, INC For: Jul 28

Thu, 30 Jul 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260730/26843511.html

A Weight-Loss Revolution Is Reshaping Bodies. This Preclinical Biotech Wants to Build What Comes Next